Skip to main content

Table 1 Risk factors of ICU death

From: Impact of ureido/carboxypenicillin resistance on the prognosis of ventilator-associated pneumonia due to Pseudomonas aeruginosa

Variables

Survivors (n = 136)

Deaths (n = 87)

P

Male sex

105 (77)

69 (79)

0.86

Age

66 (52 to 76)

70 (57 to 77)

0.04

Category at admission

Medical

90 (66)

62 (71)

0.49

 

Emergency surgery

25 (18)

17 (19)

0.76

 

Scheduled surgery

21 (15)

8 (9)

0.20

Severity score at admission

LOD

6 (4 to 8)

7 (5 to 10)

0.04

 

SAPS II

45 (36 to 53)

54 (42 to 66)

0.0001

 

SOFA

8 (6 to 10)

9 (6 to 11)

0.03

Duration of ICU stay before VAP

10 (6 to 18)

9 (5 to 18)

0.13

Duration of stay

ICU

32 (20 to 50)

26(14 to 41)

0.19

 

Hospital

57 (42 to 84)

30 (19 to 59)

<0.0001

Main diagnosis at admission

Septic shock

25 (18)

18 (21)

0.74

 

Multiple organ failure

6 (4)

6 (7)

0.26

 

Cardiac failure

5 (4)

2 (2)

0.53

 

Acute respiratory failure

47 (35)

27 (31)

0.59

 

COPD exacerbation

9 (7)

5 (6)

0.96

 

Acute renal failure

3 (2)

2 (2)

0.90

 

Scheduled surgery

9 (7)

1 (1)

0.08

Chronic illness

Cardiovascular

16 (12)

19 (22)

0.03

 

Pulmonary

31 (23)

22 (25)

0.58

 

Renal

6 (4)

4 (5)

0.90

 

Hepatic

6 (4)

7 (8)

0.29

 

Diabetes

20 (15)

9 (10)

0.73

 

At least one chronic illness

59 (43)

51 (59)

0.02

Treatment at admission

Vasopressors

84 (62)

59 (68)

0.30

 

Steroids

39 (29)

35 (40)

0.05

 

Broad-spectrum antimicrobials

88 (65)

58 (67)

0.45

 

Hemodialysis/hemofiltration

14 (10)

8 (9)

0.91

Polymicrobial VAP

34 (25)

29 (33)

0.27

SOFA score at VAP onset

5 (3 to 7)

7 (4 to 9)

0,0004

Adequate antimicrobial treatment*

J 0

53 (39)

34 (39)

0.42

 

J+1

41 (30)

25 (29)

0.66

 

J+2

32 (23)

19 (22)

0.40

Antimicrobials

Monotherapy

15 (12)

17 (22)

0.12

 

Bi or Tri antibiotic therapy

111 (82)

61 (70)

0.11

  1. Data are the number (%) of patients (minimum to maximum). ICU, intensive care unit; LOD, logistic organ dysfunction; PRPA, piperacillin resistant Pseudomonas aeruginosa; PSPA, piperacillin sensitive Pseudomonas aeruginosa; SAPS II, Simplified Acute Physiology Score version II; SOFA, Simplified Organ Failure Assessment; VAP, ventilator-associated pneumonia.
  2. (*) nb of calendar day between the suspicion of VAP/bacteriological sampling and the initiation of an antimicrobial treatment effective on recovered micro-organisms